Comparing the current results to its competitors, Astrazeneca Plc reported Revenue increase in the 4 quarter 2025 by 8.63 % year on year. The sales growth was above Astrazeneca Plc's competitors' average revenue growth of 8.29 %, achieved in the same quarter.
Astrazeneca Plc Net Income in the 4 quarter 2025 grew year on year by 45.33%, faster than the Astrazeneca Plc's competitors average income growth of 13 %
Astrazeneca Plc's Comment on Competition and Industry Peers
CTS Corporation operates in a global competitive environment, facing both domestic and international manufacturers. Competition varies by product line, with no single competitor present across all areas. Some competitors are larger and more diversified. Customer purchasing strategies, such as reducing supplier numbers or using multiple vendors, can affect CTS Corporation's sales volumes and revenues. Customers require lower costs along with higher quality, reliability, and delivery standards, presenting both opportunities and risks, including potential loss of business to competitors. CTS Corporation focuses on competing primarily in custom engineered products for major original equipment manufacturers (OEMs) and encounters typical industry risks such as technical obsolescence.
With revenue growth of 8.63 % within Overall company, Astrazeneca Plc achieved improvement in market share, within Overall company to approximately 17.28 %. << More on AZN Market Share.
*Market share is calculated based on total revenue.
Greenwich Lifesciences Inc's business model focuses on the research, development, and commercialization of innovative therapies in the field of oncology.
Immunovant Inc is a biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases by leveraging their expertise in research and development, clinical trials, and regulatory approvals. Their business model revolves around discovering innovative treatments, conducting rigorous testing, and seeking regulatory clearance to bring their products to market and improve patient outcomes.
Inovio Pharmaceuticals Inc is a biotechnology company that focuses on the development and commercialization of immunotherapies for the treatment of various diseases, including cancers and infectious diseases. Their business model involves leveraging their proprietary platforms, such as DNA-based technology and electroporation, to design and develop novel vaccines and therapies which are then advanced through clinical trials and potential partnerships for further commercialization.
Intensity Therapeutics Inc's business model involves developing and commercializing novel intratumoral cancer immunotherapy products. They aim to target and destroy tumors within the body through the direct application of their proprietary drug, leading to an enhanced immune response and potential treatment for various cancers.
Sources:
Astrazeneca Plc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Astrazeneca Plc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
